JP2010537989A5 - - Google Patents

Download PDF

Info

Publication number
JP2010537989A5
JP2010537989A5 JP2010522977A JP2010522977A JP2010537989A5 JP 2010537989 A5 JP2010537989 A5 JP 2010537989A5 JP 2010522977 A JP2010522977 A JP 2010522977A JP 2010522977 A JP2010522977 A JP 2010522977A JP 2010537989 A5 JP2010537989 A5 JP 2010537989A5
Authority
JP
Japan
Prior art keywords
composition
buprenorphine
daltons
polyethylene glycol
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010522977A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010537989A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/010318 external-priority patent/WO2009032246A2/en
Publication of JP2010537989A publication Critical patent/JP2010537989A/ja
Publication of JP2010537989A5 publication Critical patent/JP2010537989A5/ja
Pending legal-status Critical Current

Links

JP2010522977A 2007-09-03 2008-09-02 難溶性薬物の組成物及び送達方法 Pending JP2010537989A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96967207P 2007-09-03 2007-09-03
PCT/US2008/010318 WO2009032246A2 (en) 2007-09-03 2008-09-02 Particulate compositions for delivery of poorly soluble drugs

Publications (2)

Publication Number Publication Date
JP2010537989A JP2010537989A (ja) 2010-12-09
JP2010537989A5 true JP2010537989A5 (enExample) 2011-10-20

Family

ID=40377549

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010522977A Pending JP2010537989A (ja) 2007-09-03 2008-09-02 難溶性薬物の組成物及び送達方法

Country Status (14)

Country Link
US (3) US8377479B2 (enExample)
EP (2) EP2197429B9 (enExample)
JP (1) JP2010537989A (enExample)
KR (1) KR101545874B1 (enExample)
AU (1) AU2008296971B2 (enExample)
CA (1) CA2699172C (enExample)
DK (1) DK2197429T3 (enExample)
ES (1) ES2572157T3 (enExample)
HK (1) HK1226306A1 (enExample)
HU (1) HUE027537T2 (enExample)
MX (1) MX2010002409A (enExample)
PL (1) PL2197429T3 (enExample)
SI (1) SI2197429T1 (enExample)
WO (1) WO2009032246A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056500B2 (en) * 2001-10-18 2006-06-06 Nektar Therapeutics Al, Corporation Polymer conjugates of opioid antagonists
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
HUE027537T2 (en) * 2007-09-03 2016-10-28 Nanotherapeutics Inc Granular preparations for the administration of poorly soluble drugs
AU2010206724A1 (en) * 2009-01-22 2011-07-28 Nanotherapeutics, Inc. Process for preparing particles of opioids and compositions produced thereby
US20100273730A1 (en) * 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
US9125867B2 (en) * 2010-02-24 2015-09-08 Invincible Biotechnology Diversion- and/or abuse-resistant compositions and methods for making the same
GB2513060B (en) * 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
HUE045889T2 (hu) 2010-10-21 2020-01-28 Rtu Pharmaceuticals Llc Használatkész ketorolak készítmények
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
EP3215128B1 (en) 2014-11-04 2019-09-04 Innopharmax, Inc. Oral administration of unstable or poorly-absorbed drugs
US20160128997A1 (en) 2014-11-07 2016-05-12 Indivior Uk Limited Sustained-release buprenorphine formulations
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
WO2019064026A1 (en) 2017-09-29 2019-04-04 Orexo Ab NEW PHARMACEUTICAL COMPOSITIONS
US12161754B2 (en) 2017-12-20 2024-12-10 Purdue Pharma L.P. Abuse deterrent morphine sulfate dosage forms
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions
CN121401263A (zh) 2020-02-14 2026-01-27 帝国制药美国公司 外用纳洛酮组合物及其使用方法
GB202019335D0 (en) * 2020-12-08 2021-01-20 Artelo Biosciences Ltd Pharmaceutical compositions
KR20260020183A (ko) 2023-06-05 2026-02-10 나노파마슈틱스, 인크. 서방성 결정질 prx-3140의 경구 전달을 위한 조성물 및 방법

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA987588A (en) * 1970-01-02 1976-04-20 Sidney Riegelman Solid dispersions of drugs
DE2400819C2 (de) * 1974-01-09 1982-04-22 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung fester Zubereitungen von schwerlöslichen Arzneimittelwirkstoffen in feinster Verteilung
US4722941A (en) 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
ATE5852T1 (de) * 1978-11-20 1984-02-15 American Home Products Corporation Therapeutische zusammensetzungen mit gesteigerter bioverfuegbarkeit und verfahren zu deren herstellung.
US4525339A (en) 1982-10-15 1985-06-25 Hoffmann-La Roche Inc. Enteric coated oral dosage form
JPS6163614A (ja) * 1984-09-04 1986-04-01 Yamanouchi Pharmaceut Co Ltd 難溶性薬物の溶解速度向上方法
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
US5190748A (en) 1988-11-22 1993-03-02 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
AU7496991A (en) * 1990-03-20 1991-10-21 Otsuka Pharmaceutical Co., Ltd. Liposome preparation
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
FR2735658B1 (fr) * 1995-06-21 1997-09-12 Capsulis Encapsulation de composes a usage alimentaire par des tensioactifs
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US6235313B1 (en) 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US5352459A (en) * 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5318781A (en) 1993-04-06 1994-06-07 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
IE940292A1 (en) 1994-04-06 1995-10-18 Elan Corp Plc Biodegradable microcapsules and method for their manufacture
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US6368586B1 (en) 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
PT914097E (pt) * 1996-03-12 2002-06-28 Alza Corp Composicao e forma de dosagem compreendendo antagonista de opioide
GB9606188D0 (en) * 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
EP0811374A1 (en) * 1996-05-29 1997-12-10 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine
US5858531A (en) * 1996-10-24 1999-01-12 Bio Syntech Method for preparation of polymer microparticles free of organic solvent traces
US5948787A (en) * 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
TR200001942T2 (tr) 1997-12-22 2000-11-21 Euro-Celtique, S.A. Opioid agonist/antagonist kombinasyonlar
CN1204890C (zh) 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 防止阿片样物质滥用的方法
FR2774910B1 (fr) * 1998-02-16 2001-09-07 Ethypharm Lab Prod Ethiques Microgranules de sulfate de morphine, procede de fabrication et preparations pharmaceutiques
US6190699B1 (en) 1998-05-08 2001-02-20 Nzl Corporation Method of incorporating proteins or peptides into a matrix and administration thereof through mucosa
JP2000086509A (ja) * 1998-09-14 2000-03-28 Taisho Yakuhin Kogyo Kk ソファルコン含有製剤の製造方法
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US6733789B1 (en) * 1999-01-21 2004-05-11 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
US6270806B1 (en) 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6223455B1 (en) * 1999-05-03 2001-05-01 Acusphere, Inc. Spray drying apparatus and methods of use
US6406745B1 (en) * 1999-06-07 2002-06-18 Nanosphere, Inc. Methods for coating particles and particles produced thereby
CA2382577C (en) * 1999-08-27 2008-01-22 Southern Research Institute Injectable buprenorphine microparticle compositions and their use
US6480524B1 (en) * 1999-09-13 2002-11-12 Nortel Networks Limited Multiple beam antenna
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
SI2283842T1 (sl) * 2000-02-08 2015-07-31 Euro-Celtique S.A. Oralne formulacije opioidnih agonistov, varne pred zlorabo
US6248360B1 (en) 2000-06-21 2001-06-19 International Health Management Associates, Inc. Complexes to improve oral absorption of poorly absorbable antibiotics
ES2292598T3 (es) * 2000-06-27 2008-03-16 Vectura Limited Metodo para producir particulas para usar en una composicion farmaceutica.
CN1310440C (zh) * 2000-10-05 2007-04-11 三星电子株式会社 窄带时分双工码分多址移动通信系统的功率控制装置和方法
AU2002227383B2 (en) 2000-10-30 2004-07-08 Euro-Celtique S.A. Controlled release hydrocodone formulations
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
AU2003263024A1 (en) 2002-04-23 2003-11-10 Christopher Mcconville Process of forming and modifying particles and compositions produced thereby
US7157102B1 (en) * 2002-05-31 2007-01-02 Biotek, Inc. Multi-layered microcapsules and method of preparing same
US20040110781A1 (en) 2002-12-05 2004-06-10 Harmon Troy M. Pharmaceutical compositions containing indistinguishable drug components
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
WO2004087097A2 (en) * 2003-03-31 2004-10-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer
US20040191301A1 (en) * 2003-03-27 2004-09-30 Van Duren Albert Philip Transdermal device having a phase change material
DE10336400A1 (de) * 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20050048115A1 (en) * 2003-08-27 2005-03-03 Murty Mangena Buprenorphine microspheres
IL159729A0 (en) * 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents
BRPI0418427A (pt) * 2004-01-30 2007-06-12 Pfizer Italia Srl formulações farmacêuticas de matriz semi-sólida
ES2246694B1 (es) * 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
FR2878158B1 (fr) * 2004-11-24 2009-01-16 Flamel Technologies Sa Forme pharmaceutique orale, microparticulaire solide concue pour eviter le mesusage
JP2006232694A (ja) * 2005-02-23 2006-09-07 Univ Nihon 難溶性医薬とシクロデキストリン化合物からなる複合体及びその製造方法
RU2423997C9 (ru) * 2005-07-05 2011-11-20 Эббетт ГмбХ унд Ко. КГ Композиция и лекарственная форма, содержащие твердую или полутвердую матрицу
US8074906B2 (en) 2005-07-07 2011-12-13 Nanotherapeutics, Inc. Process for milling and preparing powders and compositions produced thereby
WO2007013975A2 (en) 2005-07-20 2007-02-01 Pharmorx Inc. Composition containing an opioid agonist and a partial opioid agonist, preferably buprenorphine , for controlling abuse of medications
HUE027537T2 (en) * 2007-09-03 2016-10-28 Nanotherapeutics Inc Granular preparations for the administration of poorly soluble drugs

Similar Documents

Publication Publication Date Title
JP2009143964A5 (enExample)
HRP20160368T1 (hr) Sublingvalni i bukalni filmom obložen pripravak
JP2016512248A5 (enExample)
AU2006311116C1 (en) Anti-misuse microparticulate oral pharmaceutical form
ES2572157T3 (es) Composiciones en forma de partículas para la administración de fármacos poco solubles
JP2018162284A5 (ja) 複数の被覆された粒子を含む組成物及び医薬製剤
JP2015519330A5 (enExample)
HRP20171506T1 (hr) Tableta otporna na mijenjanje koja pruža neposredno oslobađanje lijeka
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
WO2009100181A3 (en) Absorbent ingestible agents and associated methods of manufacture and use
IL200171A (en) Actriib-derived variables, pharmaceutical preparations containing them and their uses for the preparation of medicines
IL234166B (en) Isoindoline compounds, a pharmaceutical composition containing it and its use in the preparation of a medicine
NZ629468A (en) Tamper resistant immediate release formulations
EP3895699A3 (en) Pharmaceutical compositions comprising iron oxy-hydroxide
EP2497484A3 (en) A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
JP2012176990A5 (enExample)
IL206952A (en) History of Aminodia Hydrothiazine, medicinal preparations containing them, and their use in the preparation of medicines
NZ587897A (en) Drug delivery systems comprising weakly basic drugs and organic acids
JP2012517987A5 (ja) 吸入用の医薬組成物のｆｐｄ特性を設定する方法
WO2009100422A3 (en) Drug delivery system comprising microparticles and gelation system
JP2011157405A5 (enExample)
JP2012500786A5 (enExample)
IL210544A (en) Pharmaceuticals containing pyrazole derivatives, solid oral dosage forms containing them and their uses for drug preparation
JP2025503459A (ja) 疾患の治療のための噴霧乾燥された吸入可能なバイオ治療剤
HK1209371A1 (en) Oral and/or buccal composition in the form of a thin film of a weakly soluble active ingredient, method of preparing same and use of same